Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Perspectives on NASH Market

Posted by Matt Breese on Feb 20, 2018

Non-alcoholic Steatohepatitis (NASH), the severest form of non-alcoholic fatty liver disease (NAFLD), is expected to become the leading cause of liver transplantation by 2020 in the United States. This untapped market might become the next big market in the metabolic disorders segment.  
 
Currently, lifestyle modifications, such as diet and regular exercise, are the main initial therapeutic step. Bariatric surgery is considered the last option, which improves histology and causes massive weight loss. 
 
Read More

Topics: Industry Trends, Market Access, Branding & Marketing

MMIT Reality Check on Hereditary Angioedema (Feb 2018)

Posted by Matt Breese on Feb 19, 2018

According to our recent payer coverage analysis for hereditary angioedema treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Perspectives on OTC Pharma Packaging

Posted by Matt Breese on Feb 13, 2018

As the U.S. reported sales of $45.8 billion for over-the-counter (OTC) medicine in 2016, manufacturing and packaging firms saw great opportunity to capitalize in the space, according to Pharmapack. 
 
To seize the opportunity, OTC makers need to understand the changing market dynamics: growing health care costs, aging populations, demand for more affordable health care and increasing M&A activity.  
 
Read More

Topics: Industry Trends, Market Access, Branding & Marketing

MMIT Reality Check on IVIG (Feb 2018)

Posted by Matt Breese on Feb 9, 2018

According to our recent payer coverage analysis for immune globulin treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

MMIT Reality Check on HIV (Feb 2018)

Posted by Matt Breese on Feb 2, 2018

According to our recent payer coverage analysis for HIV treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on PCSK9 Inhibitors (Jan 2018)

Posted by Matt Breese on Jan 31, 2018

According to our recent payer coverage analysis for PCSK9 inhibitors, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

MMIT Reality Check on Cystic Fibrosis (Jan 2018)

Posted by Matt Breese on Jan 23, 2018

According to our recent payer coverage analysis for CF treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Trends That Matter for HGH Treatments

Posted by Matt Breese on Jan 11, 2018

In our weekly Trends that Matter series, we provide infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is human growth hormone (HGH) treatments. 

According to our recent payer coverage analysis for HGH treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

Read More

Topics: Market Access, Data & Analytics

Perspectives on Pharma Globalization

Posted by Matt Breese on Jan 9, 2018

The global pharmaceutical market is a significant contributor to the world economy. The pharma markets in the U.S., Japan, and China have the highest revenues
 
However, according to BioPharmaDive, "Increasing pricing pressures and a rapidly growing (and aging) population — means big pharma companies are looking toward untapped markets."  In 2018, we will likely see  smaller pharma companies pushing to expand their global reach.
 
Read More

Topics: Market Access

MMIT Reality Check on Growth Hormones (Jan 2018)

Posted by Matt Breese on Jan 8, 2018

According to our recent payer coverage analysis for HGH treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Data & Analytics, Branding & Marketing